Option chain shows key data for Sinopharm Gr Co's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Sinopharm Gr Co.

Sinopharm Gr Co (OTC:SHTDF) Stock, Option Chain

Founded in 2003, Sinopharm is the largest wholesaler and retailer of drugs and medical devices in China and listed on the Hong Kong Stock Exchange in 2009. It is a core subsidiary of China National Pharmaceutical Group. Sinopharm's largest operating segment is pharmaceutical distribution, making up over 70% of its total revenue by the end of 2023. In 2018, Sinopharm acquired the largest Chinese medical device distributor, China National Scientific Instruments and Materials. Now, medical device distribution accounts for over 20% of Sinopharm's total revenue. Sinopharm's downstream customers range from hospitals and other health services institutions to end-customers.

Biotech

News

Global

Media

General

BNTX

MRNA

SHTDF

SHTDY

China&#39;s Sinopharm Group (OTC: SHTDY) said Wednesday its COVID-19 vaccine candidate BBIBP-CorV — developed in partnership with Beijing Biological Products Institute Co.

China&#39;s Sinopharm COVID-19 Vaccine Shows 79.34% Efficacy

SINOPHARM GROUP CO LTD by Sinopharm Group Co. Ltd.

Sinopharm Group Co Ltd

Sinopharm Group Co (HK:1099) has released an update. Sinopharm Group Co. Ltd. has announced changes to its board committees' leadership, appointing...

Sinopharm Announces Board Committee Leadership Changes

Sinopharm Group Co (HK:1099) has released an update. Sinopharm Group Co. Ltd. has announced the composition of its board of directors, which includ...

Sinopharm Reveals Board Structure and Committees

Sinopharm Group Co (HK:1099) has released an update. Sinopharm Group Co. Ltd. has scheduled a board meeting for October 25, 2024, to review and app...

Sinopharm Group Announces Upcoming Board Meeting

Sinopharm Group Co (HK:1099) has released an update. Sinopharm Group Co. reported a slight revenue increase of 2.65% for the quarter ending Septemb...

Sinopharm Group Reports Mixed Financial Results

Sinopharm Group Co (HK:1099) has released an update. Sinopharm Group Co.'s subsidiary, China National Medical Device Co., Ltd., reported a 6.94% de...

Sinopharm Subsidiary Faces Revenue and Profit Declines

Sinopharm Group Co (HK:1099) has released an update. Sinopharm Group Co. Ltd. has released its unaudited financial results for the nine months endi...

Sinopharm Group's Asset Growth Boosts Investor Confidence

Sinopharm Group Co (HK:1099) has released an update. Sinopharm Group Co. reports a slight revenue increase of 2.65% for Sinopharm Accord, reaching ...

Sinopharm Group Co. Reports Mixed Financial Results

Sinopharm Group: The Focus Is On Working Capital And Profitability

Sinopharm Group Co Class H ( ($SHTDF) ) has released its Q3 earnings. Here is a breakdown of the information Sinopharm Group Co Class H presented t...

Sinopharm Group Reports Nine-Month Financial Results

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on BioLife Solutions (BLFS – Research Report) and Sinop...

Comments

Sinopharm Gr Co

Sinopharm Gr Co (SHTDF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga